A Randomized, Double-blind, Placebo-controlled Phase I Clinical Trial Evaluating the Safety and Immunogenicity of MVA Strain Monkeypox Attenuated Live Vaccine for Individuals Aged 18 and Above
This is a randomized, double blinded, controlled phase I clinical study. To evaluate the safety and immunogenicity of receiving two doses of MVA strain monkeypox attenuated live vaccine in individuals aged 18 years and above.
• On the day of enrollment, individuals aged 18 years or older with a history of smallpox vaccination must have been born before 1980;
• Can provide legal proof of identity;
• Be able to understand the experimental procedure and sign a written informed consent form, expressing agreement to participate in the experiment;
• Be able to participate in all planned follow-up visits and comply with all trial procedures (such as completing diary/contact cards and being able to return for visits);
• On the day of enrollment, the body temperature was less than 37.3 ℃ (axillary temperature);
• Men and women of childbearing age who have no plans to have children within 6 months and agree to take effective contraceptive measures within 6 months after receiving the experimental vaccine.